Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Ocular Hypertension Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

11 recruiting trials for Ocular Hypertension. Eligibility criteria explained in plain English.

TrialFinderData lists 11 Ocular Hypertension clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 3 is the largest group at 57% (4 studies); the largest phase groups are Phase 3: 4, Phase 2: 1, Phase 4: 1, Phase 1: 1.

Research is led by SpyGlass Pharma, Inc. (2), Sensimed AG (1), The Eye Institute of West Florida (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Bimatoprost Implant System (drug, 2 trials), followed by SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
4
Phase 3 Trials
10
Sponsors

Track Ocular Hypertension trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT04024293

Intraocular Pressure Measured by a Novel Sensing Contact Lens Versus Tonometry

While elevated intraocular pressure (IOP) is no longer part of the definition of glaucoma it remains the sole proven modifiable risk factor for the onset and progression of...

Sponsor: Sensimed AGEnrolling: 121 location
RECRUITINGNCT07390890

DSLT for Reducing Medication in Glaucoma

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication...

Sponsor: The Eye Institute of West FloridaEnrolling: 601 location
RECRUITINGNCT06629649

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

The goal of this clinical trial is to learn if implementation of an eye screening program at Federally Qualified Health Center (FQHC) clinics provides results that participants...

Sponsor: University of Alabama at BirminghamEnrolling: 18001 location
RECRUITINGPhase 3NCT07335211

Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma...

Sponsor: Huons Co., Ltd.Enrolling: 2061 location
RECRUITINGPhase 2NCT06964191

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

The goal of this clinical trial is to determine the dose of PA5108 Ocular Implant that is effective and safe for the reduction of intraocular pressure in adult patients with...

Sponsor: PolyActiva Pty LtdEnrolling: 751 location
RECRUITINGPhase 3NCT07218796

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL...

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to...

Sponsor: SpyGlass Pharma, Inc.Enrolling: 4001 location
RECRUITINGPhase 3NCT05401357

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the...

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with...

Sponsor: Amneal Pharmaceuticals, LLCEnrolling: 1689 locations
RECRUITINGPhase 4NCT07217678

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular...

Sponsor: University of MiamiEnrolling: 201 location
RECRUITINGPhase 1NCT07036510

Safety of TimoD Sustained-Release Implant in Participants With Glaucoma or Ocular Hypertension Undergoing Cataract...

The goal of this clinical trial is to test a new method to deliver an approved medicine called Timolol in the eye of participants with glaucoma or ocular hypertension and...

Sponsor: EyeD PharmaEnrolling: 181 location
RECRUITINGNCT07119580

Association Between Limbal Function and Tear Proteomics in Chronic Ocular Diseases: Focusing on Glaucoma

Background Intact corneal epithelium is important for the defense on the ocular surface, and the function of limbal stem cells is crucial to maintain its integrity. Certain...

Sponsor: National Taiwan University HospitalEnrolling: 901 location
RECRUITINGPhase 3NCT07218783

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL...

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to...

Sponsor: SpyGlass Pharma, Inc.Enrolling: 4001 location

Frequently Asked Questions

There are currently 11 clinical trials for Ocular Hypertension, with 11 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Ocular Hypertension, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 4 Phase 3 trials for Ocular Hypertension, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.